BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes

Acne Vulgaris Clinical Trial

Official title:

BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02709096
• Other study ID #: BPX-01-C02
• Status: Completed
• Phase: Phase 2
• First received: March 10, 2016
• Last updated: June 12, 2016
• Start date: April 2016
• Est. completion date: June 2016

Study information

• Verified date: March 2016
• Source: BioPharmX, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2a study which is being conducted in healthy volunteers in order to evaluate the comparative reduction of Propionibacterium acnes in-vivo following once daily topical administration of BPX-01 Minocycline 1% Topical Gel (BPX-01) or BPX-01 Vehicle control.

Description:

The objective of this study is to evaluate the comparative reduction of Propionibacterium acnes (P. acnes) in-vivo following once daily topical administration of BPX-01 Minocycline 1% Topical Gel or BPX-01 Vehicle control Gel.

A secondary objective is to assess the tolerance of the treatment regimen versus a vehicle control. Safety laboratory data (chemistry and hematology) and plasma levels of minocycline are also of significant interest to the sponsor.

This is a single center, randomized, double blind, two-cell, vehicle controlled P. acnes study. All subjects will be randomized 2:1 to 1% BPX-01 or vehicle control to be applied as a topical gel once daily for four (4) weeks.

This is a six (6) week study with a four (4) week treatment period and a two (2) week post treatment follow up visit. The clinical endpoint is in-vivo quantification of P.acnes. The safety/tolerance endpoints are; observer reported: erythema, scaling-peeling, edema, and subject reported: tightness, burning-stinging, and itching. Plasma levels of minocycline and basic hematology and chemistry laboratory values will be collected.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: June 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

1. Be a healthy, adult male and/or female volunteer 18 to 40 years of age with no past or present history of any significant disease based on PI discretion;

2. If female, must be post-menopausal, surgically sterile, or using effective birth control methods with a negative urine pregnancy test at the Screening and Baseline visits (female subjects of childbearing potential only);

3. Show a high degree of fluorescence of the face under a Wood's lamp at the screening visit.

4. Be willing to refrain from using antimicrobial topical products for the duration of study participation;

5. Be willing to return to the study center for all study visits;

6. Be willing to follow all study instructions and adhere to study restrictions;

7. Provide informed consent to the study procedures and restrictions

Exclusion Criteria:

1. Have a history of skin disease or presence of skin condition the PI believes would interfere with the study;

2. Females who report that they are pregnant, planning a pregnancy or breastfeeding or those females who are of child bearing potential, that test positive with a urine pregnancy test;

3. Have conditions or factors that the PI believes may affect the response of the skin or the interpretation of the results;

4. Participated in any clinical study within the previous 30 days, be concurrently participating in other studies, or be involved in any aspect of test administration;

5. Use of topical or systemic antibiotics or other products within the previous 4 weeks prior to baseline, that influence P. acnes counts;

6. Are known to be allergic to any of the test product(s) or any components in the test product(s);

7. Have a history of significant medical condition/disease that the PI believes may affect the response of the skin or the interpretation of the results;

8. Has any other condition that, in the opinion of the Investigator or his designee, could interfere with the subject's ability to use the treatment as instructed, alter their treatment response, or affect their ability to complete the study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acne Vulgaris

Intervention

Drug:
• BPX-01, 1% Topical Gel
topical gel, applied to the forehead, cheeks, nose and chin
• BPX-01 Vehicle Gel
topical gel, applied to the forehead, cheeks, nose and chin

Locations

Country	Name	City	State
United States	KGL Skin Study Center	Broomall	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
BioPharmX, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Logarithmic Change in Colony Counts of Facial Propionibacterium acnes	P. Acnes cultures will be collected using the modified Kligman Method at each study visit. After plating, the samples will be cultured for 7 days and then evaluated.	Cultures will be evaluated at Baseline, Week 1, Week 2, Week 4 and Week 6	No